CDH13 and HCRTR2 may be associated with hypersomnia symptom of bipolar depression: A genome-wide functional enrichment pathway analysis

Psychiatry Investigation

Volumn 12, Issue 3, 2015, Pages 402-407

  Cho, Chul Hyun ^a   Lee, Heon Jeong ^a   Woo, Hyun Goo ^b   Choi, Ji Hye ^b   Greenwood, Tiffany A ^c   Kelsoe, John R ^c,d  

^a Korea University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Bipolar depression; Bipolar disorder; Functional enrichment pathway analysis; Genome wide association study; Hypersomnia

Indexed keywords

ARTICLE; BIPOLAR DEPRESSION; CELL ADHESION; GENE FREQUENCY; GENE ONTOLOGY; GENETIC ASSOCIATION; HYPERSOMNIA; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTIC TRANSMISSION;

EID: 84937838562     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2015.12.3.402     Document Type: Article

References (57)

1. Gutierrez-Rojas L, Gurpegui M, Ayuso-Mateos JL, Gutierrez-Ariza JA, Ruiz-Veguilla M, Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord 2008; 10:625-634.
2. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008;13:197-207.
3. Smith EN, Koller DL, Panganiban C, Szelinger S, Zhang P, Badner JA, et al. Genome-wide association of bipolar disorder suggests an enrichment of replicable associations in regions near genes. PLoS Genet 2011;7: e1002134.
4. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-1517.
5. McQueen MB, Devlin B, Faraone SV, Nimgaonkar VL, Sklar P, Smoller JW, et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet 2005;77:582-595.
6. Kripke DF, Nievergelt CM, Joo E, Shekhtman T, Kelsoe JR. Circadian polymorphisms associated with affective disorders. J Circadian Rhythms 2009;7:2.
7. McCarthy MJ, Nievergelt CM, Kelsoe JR, Welsh DK. A survey of genomic studies supports association of circadian clock genes with bipolar disorder spectrum illnesses and lithium response. PLoS One 2012; 7:e32091.
8. Kennedy SH, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res 1996;63:219-222.
9. Kripke DF, Mullaney DJ, Atkinson M, Wolf S. Circadian rhythm disorders in manic-depressives. Biol Psychiatry 1978;13:335-351.
10. Leibenluft E, Albert PS, Rosenthal NE, Wehr TA. Relationship between sleep and mood in patients with rapid-cycling bipolar disorder. Psychiatry Res 1996;63:161-168.
11. Harvey AG, Mullin BC, Hinshaw SP. Sleep and circadian rhythms in children and adolescents with bipolar disorder. Dev Psychopathol 2006; 18:1147-1168.
12. Mitterauer B. Clock genes, feedback loops and their possible role in the etiology of bipolar disorders: an integrative model. Med Hypotheses 2000;55:155-159.
13. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849-859; discussion 863-864.
14. Sanders AR, Levinson DF, Duan J, Dennis JM, Li R, Kendler KS, et al. The Internet-based MGS2 control sample: self report of mental illness. Am J Psychiatry 2010;167:854-865.
15. Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry 2009;14: 755-763.
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 2007;81:559-575.
17. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009;5:e1000529.
18. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
19. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
20. Takeuchi T, Misaki A, Liang SB, Tachibana A, Hayashi N, Sonobe H, et al. Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells. J Neurochem 2000;74:1489-1497.
21. Redies C. Cadherins in the central nervous system. Prog Neurobiol 2000;61:611-648.
22. Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacology 2001;25(5 Suppl):S5-S13.
23. Drgon T, Montoya I, Johnson C, Liu QR, Walther D, Hamer D, et al. Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. Mol Med 2009;15:21-27.
24. Johnson C, Drgon T, Walther D, Uhl GR. Genomic regions identified by overlapping clusters of nominally-positive SNPs from genome-wide studies of alcohol and illegal substance dependence. PLoS One 2011; 6:e19210.
25. Hart AB, Engelhardt BE, Wardle MC, Sokoloff G, Stephens M, de Wit H, et al. Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PLoS One 2012;7:e42646.
26. Liu QR, Drgon T, Johnson C, Walther D, Hess J, Uhl GR. Addiction molecular genetics: 639,401 SNP whole genome association identifies many “cell adhesion” genes. Am J Med Genet B Neuropsychiatr Genet 2006;141B:918-925.
27. Treutlein J, Cichon S, Ridinger M, Wodarz N, Soyka M, Zill P, et al. Genome- wide association study of alcohol dependence. Arch Gen Psychiatry 2009;66:773-784.
28. Uhl GR, Drgon T, Johnson C, Walther D, David SP, Aveyard P, et al. Genome- wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics 2010;11:357-367.
29. Edwards AC, Aliev F, Bierut LJ, Bucholz KK, Edenberg H, Hesselbrock V, et al. Genome-wide association study of comorbid depressive syndrome and alcohol dependence. Psychiatr Genet 2012;22:31-41.
30. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-552.
31. Salloum IM, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000;2:269-280.
32. Jee SH, Sull JW, Lee JE, Shin C, Park J, Kimm H, et al. Adiponectin concentrations: a genome-wide association study. Am J Hum Genet 2010;87:545-552.
33. Wu Y, Li Y, Lange EM, Croteau-Chonka DC, Kuzawa CW, McDade TW, et al. Genome-wide association study for adiponectin levels in Filipino women identifies CDH13 and a novel uncommon haplotype at KNG1-ADIPOQ. Hum Mol Genet 2010;19:4955-4964.
34. Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, Lai S, et al. Genome- wide association scan of trait depression. Biol Psychiatry 2010; 68:811-817.
35. Leo R, Di Lorenzo G, Tesauro M, Cola C, Fortuna E, Zanasi M, et al. Decreased plasma adiponectin concentration in major depression. Neurosci Lett 2006;407:211-213.
36. Narita K, Murata T, Hamada T, Takahashi T, Kosaka H, Sudo S, et al. Adiponectin multimer distribution, not absolute amount of plasma, correlates with depression severity in healthy elderly subjects. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:124-127.
37. Diniz BS, Teixeira AL, Campos AC, Miranda AS, Rocha NP, Talib LL, et al. Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res 2012;46:1081-1085.
38. Taylor VH, Macqueen GM. The role of adipokines in understanding the associations between obesity and depression. J Obes 2010;2010.
39. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74:15-25.
40. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003;88:2714-2718.
41. Kapsimalis F, Basta M, Varouchakis G, Gourgoulianis K, Vgontzas A, Kryger M. Cytokines and pathological sleep. Sleep Med 2008;9:603-614
42. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-585.
43. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015.
44. Eriksson KS, Sergeeva OA, Haas HL, Selbach O. Orexins/hypocretins and aminergic systems. Acta Physiol (Oxf) 2010;198:263-275.
45. Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs 2013;27: 411-422.
46. Allard JS, Tizabi Y, Shaffery JP, Manaye K. Effects of rapid eye movement sleep deprivation on hypocretin neurons in the hypothalamus of a rat model of depression. Neuropeptides 2007;41:329-337.
47. Feng P, Vurbic D, Wu Z, Strohl KP. Brain orexins and wake regulation in rats exposed to maternal deprivation. Brain Res 2007;1154:163-172.
48. Nocjar C, Zhang J, Feng P, Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience 2012;218:138-153.
49. Lutter M, Krishnan V, Russo SJ, Jung S, McClung CA, Nestler EJ. Orexin signaling mediates the antidepressant-like effect of calorie restriction. J Neurosci 2008;28:3071-3075.
50. Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 2012;198: 79-121.
51. Ito N, Yabe T, Gamo Y, Nagai T, Oikawa T, Yamada H, et al. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 2008;157:720-732.
52. Howell OW, Doyle K, Goodman JH, Scharfman HE, Herzog H, Pringle A, et al. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem 2005;93:560-570.
53. Ito N, Yabe T, Nagai T, Oikawa T, Yamada H, Hanawa T. A possible mechanism underlying an antidepressive-like effect of Kososan, a Kampo medicine, via the hypothalamic orexinergic system in the stress-induced depression-like model mice. Biol Pharm Bull 2009;32:1716-1722.
54. Adidharma W, Leach G, Yan L. Orexinergic signaling mediates lightinduced neuronal activation in the dorsal raphe nucleus. Neuroscience 2012;220:201-207.
55. Pail G, Huf W, Pjrek E, Winkler D, Willeit M, Praschak-Rieder N, et al. Bright-light therapy in the treatment of mood disorders. Neuropsychobiology 2011;64:152-162.
56. Mitchell PB, Wilhelm K, Parker G, Austin MP, Rutgers P, Malhi GS. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry 2001;62:212-216; quiz 217.
57. Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE, et al. Hcrtr1 and 2 signaling differentially regulates depressionlike behaviors. Behav Brain Res 2011;222:289-294.